{"nctId":"NCT01600716","briefTitle":"Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)","startDateStruct":{"date":"2012-06-13","type":"ACTUAL"},"conditions":["Urinary Incontinence","Multiple Sclerosis","Neurogenic Bladder"],"count":144,"armGroups":[{"label":"OnabotulinumtoxinA","type":"EXPERIMENTAL","interventionNames":["Biological: OnabotulinumtoxinA"]},{"label":"Placebo (Normal Saline)","type":"OTHER","interventionNames":["Biological: OnabotulinumtoxinA","Drug: Placebo (Normal Saline)"]}],"interventions":[{"name":"OnabotulinumtoxinA","otherNames":["BOTOXÂ®","botulinum toxin Type A"]},{"name":"Placebo (Normal Saline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 3 episodes of urinary incontinence over a 3-day period\n* History of Multiple Sclerosis (MS)\n* Urinary incontinence not adequately controlled by anticholinergic medication\n\nExclusion Criteria:\n\n* Current use of intermittent catheter or indwelling catheter to manage urinary incontinence\n* Previous or current botulinum toxin therapy of any serotype for any urological condition\n* Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks\n* Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes","description":"Incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary. The number of episodes of urinary incontinence is recorded over a 3-day period the week of the study visit. A negative number change from baseline indicates a reduction in incontinence episodes (improvement) and a positive number change indicates an increase in incontinence episodes (worsening).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":"3.167"},{"groupId":"OG001","value":"4.32","spread":"2.422"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.34","spread":"2.881"},{"groupId":"OG001","value":"-1.10","spread":"2.083"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Maximum Cystometric Capacity (MCC)","description":"MCC represents the maximum volume of urine the bladder holds. A positive number change from baseline represents an improvement (increase) in the maximum volume of urine the bladder holds and a negative number change from baseline represents a worsening (decrease) in the maximum volume of urine the bladder holds.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246.4","spread":"138.49"},{"groupId":"OG001","value":"245.7","spread":"133.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.2","spread":"139.25"},{"groupId":"OG001","value":"-1.8","spread":"93.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Maximum Detrusor Pressure During the First Involuntary Detrusor Contraction (IDC)","description":"Maximum detrusor pressure represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. A negative number change from baseline indicates an improvement in pressure and a positive number change from baseline indicates a worsening in pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":"34.90"},{"groupId":"OG001","value":"36.1","spread":"37.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.6","spread":"37.61"},{"groupId":"OG001","value":"3.7","spread":"33.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Incontinence Quality of Life Instrument (I-QOL) Total Summary Score","description":"The I-QOL is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL, and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0=worst QOL and 100=best QOL). A positive change from baseline represents an improvement and a negative change from baseline represents a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.43","spread":"16.337"},{"groupId":"OG001","value":"34.24","spread":"21.163"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.39","spread":"26.499"},{"groupId":"OG001","value":"9.92","spread":"15.863"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Treatment Effect Through Week 52","description":"The duration of treatment effect is the time to patient request for retreatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":66},"commonTop":["Urinary tract infection","Urinary Retention","Bacteriuria","Residual Urine Volume","Leukocyturia"]}}}